The San Antonio Cancer Institute Flow Cytometry Core Facility is located within the University of Texas Health Science Center at San Antonio (UTHSCSA) Institutional Flow Cytometry Facility. The core includes a state-of-the-art rapid cell sorter (FACSstar Plus; 10,000 events/sec) and a new FACScalibur instrument for 3-4 color analysis. The facility is equipped with two workstations and two advanced printers (Tektronix). The Director of the combined facilities is Dr. Yair Gazitt (Medicine/Hematology, UTHSCSA), who has used flow cytometry for analysis and sorting since 1977 and has been the Director of the institutional Flow Cytometry Core Facility for the past five years. The core supports cell sorting and cloning of specific subpopulations of lymphocytes, various tumor cells, osteoclasts, osteoblasts, stem cells and kidney cells. This includes mouse models and human studies. Basic services offered to the San Antonio Cancer Institute consist of immunophenotyping (including leukemia, lymphoma breast cancer cells), DNA content and cell cycle analysis (including apoptosis analysis), cell sorting, multiparameter analysis (3-3 color), Ca++ fluxes, measurement of MDR-1 function and apoptosis. The facility has been instrumental in the success of several key established Cancer Center investigators and work is ongoing to develop new techniques in response to needs identified by SACI members. Protocols currently under development include sorting by DNA content and multiparameter cytokine quantitation using fluorescent microspheres (Becton Dickinson), a fluorescence based """"""""ELISA"""""""" assay.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA054174-12
Application #
6651725
Study Section
Project Start
2002-08-26
Project End
2003-07-31
Budget Start
Budget End
Support Year
12
Fiscal Year
2002
Total Cost
$254,104
Indirect Cost
Name
Ctrc Research Foundation
Department
Type
DUNS #
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Yu, Xiaojie; Zhang, Yiqiang; Ma, Xiuye et al. (2018) miR-195 potentiates the efficacy of microtubule-targeting agents in non-small cell lung cancer. Cancer Lett 427:85-93
Ankerst, Donna P; Goros, Martin; Tomlins, Scott A et al. (2018) Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. Eur Urol Focus :
Arora, Sukeshi Patel; Mahalingam, Devalingam (2018) Immunotherapy in colorectal cancer: for the select few or all? J Gastrointest Oncol 9:170-179
Arellano, Luisa M; Arora, Sukeshi Patel (2018) Systemic Treatment of Advanced Hepatocellular Carcinoma in Older Adults. J Nat Sci 4:
Du, Liqin; Zhao, Zhenze; Suraokar, Milind et al. (2018) LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer. Oncotarget 9:29601-29618
Ankerst, Donna P; Straubinger, Johanna; Selig, Katharina et al. (2018) A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. Eur Urol 74:197-203
Sun, Xiujie; Gupta, Kshama; Wu, Bogang et al. (2018) Tumor-extrinsic discoidin domain receptor 1 promotes mammary tumor growth by regulating adipose stromal interleukin 6 production in mice. J Biol Chem 293:2841-2849
Horning, Aaron M; Wang, Yao; Lin, Che-Kuang et al. (2018) Single-Cell RNA-seq Reveals a Subpopulation of Prostate Cancer Cells with Enhanced Cell-Cycle-Related Transcription and Attenuated Androgen Response. Cancer Res 78:853-864
Gong, Siqi; Tomusange, Khamis; Kulkarni, Viraj et al. (2018) Anti-HIV IgM protects against mucosal SHIV transmission. AIDS 32:F5-F13
Gelfond, Jonathan; Goros, Martin; Hernandez, Brian et al. (2018) A System for an Accountable Data Analysis Process in R. R J 10:6-21

Showing the most recent 10 out of 989 publications